$CYRX
Cryoport, Inc. Stock $cyrx

$cyrx Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000114420414067082 Filed on November 12, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2013 Q3
Revenue	$975.0K	$825.0K	$580.0K
YoY Change	28.8%	42.24%	147.86%
Cost Of Revenue	$740.7K	$600.0K	$507.7K
YoY Change	25.48%	18.18%	47.41%
Gross Profit	$235.0K	$225.0K	$72.00K
YoY Change	40.72%	212.5%	-164.86%
Gross Profit Margin	24.1%	27.27%	12.41%
Selling, General & Admin	$1.493M	$1.511M	$1.240M
YoY Change	14.34%	21.79%	-7.52%
% of Gross Profit	635.21%	671.43%	1722.8%
Research & Development	$99.05K	$89.28K	$118.4K
YoY Change	-16.4%	-24.62%	16.51%
% of Gross Profit	42.15%	39.68%	164.49%
Depreciation & Amortization	$50.00K	$50.00K	$61.82K
YoY Change	-2.87%	-19.13%	-33.31%
% of Gross Profit	21.28%	22.22%	85.87%
Operating Expenses	$1.592M	$1.600M	$1.359M
YoY Change	11.78%	17.75%	-5.83%
Operating Profit	-$1.357M	-$1.375M	-$1.287M
YoY Change	7.96%	6.84%	-17.18%
Interest Expense	$48.61K	$7.854K	$512.8K
YoY Change	52.91%	-98.47%	4260.71%
% of Operating Profit
Other Income/Expense, Net	-$1.906K	-$1.876K	$0.00
YoY Change			-100.0%
Pretax Income	-$1.408M	-$1.385M	-$14.96M
YoY Change	-23.51%	-90.74%	864.45%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.408M	-$1.385M	-$14.96M
YoY Change	-23.48%	-90.74%	864.54%
Net Earnings / Revenue	-144.41%	-167.88%	-2579.31%
Basic Earnings Per Share
Diluted Earnings Per Share	-$282.0K	-$276.0K	-$4.589M
COMMON SHARES
Basic Shares Outstanding	60.06M shares	60.04M shares	38.26M shares
Diluted Shares Outstanding			40.52M shares

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$800.0K	$100.0K	$500.0K
YoY Change	300.0%	-80.0%	-70.59%
Cash & Equivalents	$773.9K	$103.3K	$532.5K
Short-Term Investments
Other Short-Term Assets	$100.0K	$85.31K	$40.69K
YoY Change	-2.65%	109.69%
Inventory	$100.0K	$58.80K	$43.31K
Prepaid Expenses
Receivables	$400.0K	$408.1K	$387.7K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.400M	$655.5K	$1.004M
YoY Change	41.65%	-34.72%	-47.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$300.0K	$393.4K	$516.6K
YoY Change	-35.36%	-23.86%	-13.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$0.00
YoY Change
Total Long-Term Assets	$500.0K	$549.8K	$753.2K
YoY Change	-24.54%	-27.01%	-16.31%
TOTAL ASSETS
Total Short-Term Assets	$1.400M	$655.5K	$1.004M
Total Long-Term Assets	$500.0K	$549.8K	$753.2K
Total Assets	$1.900M	$1.205M	$1.757M
YoY Change	15.08%	-31.41%	-37.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$700.0K	$700.0K	$600.0K
YoY Change	-22.22%	16.67%	20.0%
Accrued Expenses	$600.0K	$500.0K	$300.0K
YoY Change	50.0%	66.67%	200.0%
Deferred Revenue
YoY Change
Short-Term Debt	$300.0K	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.300M	$1.300M	$100.0K
YoY Change	160.0%	1200.0%	0.0%
Total Short-Term Liabilities	$3.000M	$2.579M	$1.043M
YoY Change	69.13%	147.36%	48.94%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$1.300M
YoY Change	-100.0%	-100.0%	0.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$1.300M
YoY Change	-100.0%	-100.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.000M	$2.579M	$1.043M
Total Long-Term Liabilities	$0.00	$0.00	$1.300M
Total Liabilities	$3.000M	$2.600M	$2.335M
YoY Change	-1.68%	11.34%	11.2%
SHAREHOLDERS EQUITY
Retained Earnings		-$92.03M	-$82.59M
YoY Change		11.42%
Common Stock		$90.65M	$82.02M
YoY Change		10.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.100M	-$1.374M	-$577.9K
YoY Change
Total Liabilities & Shareholders Equity	$1.900M	$1.205M	$1.757M
YoY Change	15.08%	-31.41%	-37.24%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2013 Q3
OPERATING ACTIVITIES
Net Income	-$1.408M	-$1.385M	-$14.96M
YoY Change	-23.48%	-90.74%	864.54%
Depreciation, Depletion And Amortization	$50.00K	$50.00K	$61.82K
YoY Change	-2.87%	-19.13%	-33.31%
Cash From Operating Activities	-$1.070M	-$850.0K	-$1.150M
YoY Change	27.38%	-26.09%	-7.26%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$70.00K	-$10.00K
YoY Change		600.0%	0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$70.00K	-$10.00K
YoY Change		600.0%	0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.730M	860.0K	1.450M
YoY Change	220.37%	-40.69%	-2171.43%
NET CHANGE
Cash From Operating Activities	-1.070M	-850.0K	-1.150M
Cash From Investing Activities	0.000	-70.00K	-10.00K
Cash From Financing Activities	1.730M	860.0K	1.450M
Net Change In Cash	660.0K	-60.00K	290.0K
YoY Change	-320.0%	-120.69%	-121.97%
FREE CASH FLOW
Cash From Operating Activities	-$1.070M	-$850.0K	-$1.150M
Capital Expenditures	$0.00	-$70.00K	-$10.00K
Free Cash Flow	-$1.070M	-$780.0K	-$1.140M
YoY Change	27.38%	-31.58%	-7.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	369581	USD
	us-gaap	Net Income Loss NetIncomeLoss	-16283185	USD
CY2014Q1	us-gaap	Inventory Net InventoryNet	29703	USD
CY2014Q1	us-gaap	Other Assets Current OtherAssetsCurrent	196505	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	180086	USD
CY2014Q1	us-gaap	Assets Assets	1709950	USD
CY2014Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	579678	USD
CY2014Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1622359	USD
CY2014Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	1358120	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4014445	USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	59980	USD
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	83512399	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85876874	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	-2304495	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1709950	USD
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2014Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	24600	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-14959648	USD
	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	0	USD
	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	2468813	USD
CY2013Q3	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	0	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
CY2013Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16283185	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6250433	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14959648	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38589663	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	60019290	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39110774	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2014Q1	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	555500	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include allowances for doubtful accounts, recoverability of long-lived assets, allowance for inventory obsolescence, deferred taxes and their accompanying valuations and valuation of equity instruments.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	60058	USD
CY2014Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	150000	shares
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103343	USD
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	515825	USD
CY2014Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	408080	USD
CY2014Q3	us-gaap	Inventory Net InventoryNet	58804	USD
CY2014Q3	us-gaap	Other Assets Current OtherAssetsCurrent	85312	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	1111614	USD
CY2014Q3	us-gaap	Assets Current AssetsCurrent	655539	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	408892	USD
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	393372	USD
CY2014Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	156407	USD
CY2014Q1	us-gaap	Deposits Assets DepositsAssets	9358	USD
CY2014Q3	us-gaap	Deposits Assets DepositsAssets	0	USD
CY2014Q3	us-gaap	Assets Assets	1205318	USD
CY2014Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	703084	USD
CY2014Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	454288	USD
CY2014Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	549659	USD
CY2014Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	USD
CY2014Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	1326188	USD
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2578931	USD
CY2014Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	90593704	USD
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-92027710	USD
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	-1373613	USD
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1205318	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-1384759	USD
CY2014Q3	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	1727027	USD
CY2014Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	71874	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3183660	USD
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13960989	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19224480	shares
CY2014	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
CY2014Q3	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	507500	USD
	cyrx	Increased Principal Payment In Every Nine Months IncreasedPrincipalPaymentInEveryNineMonths	2500	USD
CY2014Q3	cyrx	Maximum Amount Of Aggregate Monthly Principal Payment MaximumAmountOfAggregateMonthlyPrincipalPayment	10000	USD
CY2014Q3	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	8000	USD
	us-gaap	Related Party Transaction Rate RelatedPartyTransactionRate	0.06	pure
CY2006Q2	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	2500	USD
CY2014Q3	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	24000	USD
	cyrx	Minimum Amount Of Additional Compensation MinimumAmountOfAdditionalCompensation	2000000	USD
CY2014Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	87241099	shares
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
	us-gaap	Interest Expense Debt InterestExpenseDebt	826900	USD
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60057846	shares
CY2014Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	19200	USD
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	60048933	shares
CY2014Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2014Q2	cyrx	Convertible Preferred Stock Designated ConvertiblePreferredStockDesignated	800000	shares
CY2014Q3	cyrx	Preferred Stock Unpaid Dividends Per Share Not Declared PreferredStockUnpaidDividendsPerShareNotDeclared	0.96
	cyrx	Rate Of One Share For Each Dividend RateOfOneShareForEachDividend	0.40
	cyrx	Gross Proceeds From Issuance Of Preferred Stock GrossProceedsFromIssuanceOfPreferredStock	2100000	USD
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
	us-gaap	Cost Of Revenue CostOfRevenue	1197275	USD
CY2013Q3	us-gaap	Cost Of Revenue CostOfRevenue	507725	USD
CY2014Q3	us-gaap	Cost Of Revenue CostOfRevenue	600042	USD
	us-gaap	Gross Profit GrossProfit	126744	USD
	us-gaap	Gross Profit GrossProfit	564313	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	1700000	USD
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	171301	shares
CY2014Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1370408	shares
CY2014Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.50
	cyrx	Shares And Warrants Issued Description SharesAndWarrantsIssuedDescription	The shares and warrants were issued as a unit (a Unit) consisting of (i) one share of Class A Convertible Preferred Stock and (ii) one warrant to purchase eight (8) shares of the Companys common stock at an exercise price of $0.50 per share, which are immediately exercisable and may be exercised at any time on or before March 31, 2019.
	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.05	pure
CY2014Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1793000	USD
CY2014	cyrx	Units Issued Per Units To Investors UnitsIssuedPerUnitsToInvestors	12.00
CY2014Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	10.80
CY2014Q3	cyrx	Warrants Fair Value WarrantsFairValue	2500000	USD
CY2014Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	334909	shares
CY2014Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2679272	shares
	us-gaap	Convertible Preferred Stock Converted To Other Securities ConvertiblePreferredStockConvertedToOtherSecurities	87200000	USD
CY2014Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	184750	USD
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	59979954	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60057846	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59979954	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.39
	us-gaap	Sales Revenue Net SalesRevenueNet	1067790	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	1761588	USD
CY2013Q3	us-gaap	Sales Revenue Net SalesRevenueNet	579827	USD
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	825000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	941046	USD
CY2013Q3	us-gaap	Gross Profit GrossProfit	72102	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	224958	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2462487	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2938558	USD
CY2013Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1240413	USD
CY2014Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1510708	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	211079	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	168523	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	118436	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	89279	USD
	us-gaap	Operating Expenses OperatingExpenses	2673566	USD
	us-gaap	Operating Expenses OperatingExpenses	3107081	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	1358849	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	1599987	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2546822	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2542768	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1286747	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1375029	USD
	us-gaap	Interest Expense InterestExpense	594995	USD
	us-gaap	Interest Expense InterestExpense	1136732	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	512776	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	7854	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-923	USD
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1876	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	19649	USD
CY2013Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	892	USD
CY2014Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-16283185	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3680423	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-14959648	USD
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1384759	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1600	USD
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	99597	USD
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3682023	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	354452	USD
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-2809	USD
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-1864	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	48000	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	48000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2424692	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1576195	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	178990	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	105186	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	515381	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1110013	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	331220	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	465	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	170572	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-107280	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4093	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	29101	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	9627	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	7921	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-221520	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	143868	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	124995	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	95371	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	76403	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	25964	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2317831	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1774582	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	137496	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	67851	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-137496	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-67851	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1662564	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	100000	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	11631	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2615301	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	50000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	242609	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-30635	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-266238	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	563104	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	532469	USD
	cyrx	Offering Costs In Connection With Equity Financing Included In Accounts Payable OfferingCostsInConnectionWithEquityFinancingIncludedInAccountsPayable	0	USD
	cyrx	Offering Costs In Connection With Equity Financing Included In Accounts Payable OfferingCostsInConnectionWithEquityFinancingIncludedInAccountsPayable	9658	USD
	cyrx	Deferred Financing Costs In Connection With Convertible Debt Payable Included In Accounts Payable DeferredFinancingCostsInConnectionWithConvertibleDebtPayableIncludedInAccountsPayable	27743	USD
	cyrx	Deferred Financing Costs In Connection With Convertible Debt Payable Included In Accounts Payable DeferredFinancingCostsInConnectionWithConvertibleDebtPayableIncludedInAccountsPayable	0	USD
	cyrx	Debt Conversion Converted Instrument Amount Warrant Issued DebtConversionConvertedInstrumentAmountWarrantIssued	199170	USD
	cyrx	Debt Conversion Converted Instrument Amount Warrant Issued DebtConversionConvertedInstrumentAmountWarrantIssued	0	USD
	cyrx	Convertible Preferred Stock Beneficial Conversion Feature And Fair Value Of Warrants Issued ConvertiblePreferredStockBeneficialConversionFeatureAndFairValueOfWarrantsIssued	0	USD
	cyrx	Convertible Preferred Stock Beneficial Conversion Feature And Fair Value Of Warrants Issued ConvertiblePreferredStockBeneficialConversionFeatureAndFairValueOfWarrantsIssued	2468813	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	3977175	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Note 2. Nature of the Business</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">   <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Cryoport Inc. is a Nevada corporation originally incorporated under the name G.T.5-Limited (“GT5”) on May 25, 1990. In connection with a Share Exchange Agreement, on March 15, 2005 we changed our name to Cryoport, Inc. and acquired all of the issued and outstanding shares of common stock of Cryoport Systems, Inc., a California corporation. Cryoport Systems, Inc., which was originally formed in 1999 as a California limited liability company, and subsequently reorganized into a California corporation on December 11, 2000, remains an operating company under Cryoport, Inc. We became “publicly held” by the reverse merger with GT5 described above. Over time the Company has transitioned from being a development company to a fully operational public company, providing global cryogenic logistics solutions to the biotechnology and life sciences industries.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Through a combination of purpose-built proprietary packaging, information technology and specialized cold chain logistics knowhow, we provide cryogenic logistics solutions to the life sciences industry. We view our solutions as disruptive to the “older technologies” of liquid nitrogen and dry ice, in that our solutions are comprehensive and combine our competencies in configurations that are customized to our clients requirements. We provide comprehensive, reliable, economic alternatives to all existing solutions and services utilized for frozen shipping in the life sciences industry (e.g., stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other items that require continuous exposure to frozen or cryogenic temperatures). We have the ability to monitor, record and archive crucial information for each shipment that can be used for scientific and/or regulatory purposes.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Our Cryoport Express® Solutions include a sophisticated cloud-based logistics management software platform that we have branded as the Cryoportal. The Cryoportal supports the management of an entire shipment process through a single interface, including initial order input, document preparation, customs clearance, courier management, shipment tracking, issue resolution, and delivery. It provides unique and incisive information dashboards and validation documentation for every shipment. The Cryoportal records and retains a fully documented “chain-of-custody” and, at the client’s option, “chain-of-condition” for every shipment, helping ensure that quality, safety, efficacy, and stability of shipped commodities are maintained throughout the process. This recorded and archived information allows our clients to meet exacting requirements necessary for scientific work and for regulatory purposes.</font></div>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Our Cryoport Express® Solutions also include our liquid nitrogen dry vapor shippers. We have branded our packaging as our Cryoport Express® Shippers. Cryoport Express® Shippers are cost-effective and reusable cryogenic transport containers (our standard shipper is a patented vacuum flask) utilizing an innovative application of “dry vapor” liquid nitrogen (“LN2”) technology. Cryoport Express® Shippers are International Air Transport Association (“IATA”) certified and validated to maintain stable temperatures of minus 150° C and below for a 10-plus day dynamic shipment period. The Company currently features three Cryoport Express® Shipper packages, the Standard Dry Shipper (holding up to 75-2.0 ml vials), the High Volume Dry Shipper (holding up to 500-2.0 ml vials) and the recently introduced Cryoport Express® CXVC1 Shipper (holding up to 1,500-2.0ml vials). We assist clients with internal secondary packaging as well (e.g., vials, canes, straws, plates, etc.)</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Our most used solution is the “turnkey” solution, which can be accessed through our cloud-based Cryoportal or by contacting Cryoport Client Care for order entry. Once an order is placed, we ship a fully charged Cryoport Express® Shipper package to the client who conveniently loads their frozen commodity into the inner chamber of the shipper package.  The customer then closes the shipper package and reseals the shipping box displaying the next recipient’s address (“Flap A”) for pre-arranged carrier pick up.  Cryoport arranges for the pick-up of the parcel by a shipping service provider for delivery to the client’s intended recipient.  The recipient simply opens the shipper package and removes the frozen commodity that has been shipped.  The recipient then reseals the package, displaying the nearest Cryoport Operations Center address (“Flap B”) and sets it out for pre-arranged carrier pick-up. The Cryoport Express® Shipper is returned to the Cryoport Operations Center for cleaning, quality assurance testing, recharging and reuse.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Recognizing that clients in the life sciences industry have varying requirements, in late 2012, we shifted our focus from being a simple service providing cryogenic shippers and software to being a comprehensive cryogenic logistics solutions provider to the life sciences industry. This was accomplished by unbundling our technologies, establishing customer facing solutions, and taking a consultative approach to the market. Today, in addition to our standard “Turn-key Solution,” we also provide the following customer facing, value-added solutions to address our various clients’ needs:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif">  </div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> “<strong><i>Customer Staged Solution</i></strong>,” under which we supply an inventory of our Cryoport Express<sup style="font-style:normal">®</sup> Shipper packages to our customer, in an uncharged state, enabling our customer (after training/certification) to charge them with liquid nitrogen and use our Cryoportal to enter orders with shipping and delivery service providers for the transportation of the package. Once the order is released, our customer services professionals monitor the shipment and the return of the shipper for cleaning, quality assurance testing and reuse.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif">  </div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> “<strong><i>Customer Managed Solution</i></strong>,” a limited customer implemented solution whereby we supply our Cryoport Express<sup style="font-style:normal">®</sup> Shippers packages to clients in a fully charged state, but leaving it to the client to manage the shipping, including the selection of the shipping and delivery service provider and the return of the shipper to us. Under this solution, the customer accepts a significant level of risk for a successful shipment.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif">  </div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> “<strong><i>Powered by Cryoport</i></strong><sup style="font-style:normal">SM</sup>,” is made available to providers of shipping and delivery services who seek to offer a “branded” cryogenic logistics solution as part of their service offerings. This solution can be private labeled as long as the client meets the minimum required shipping volume and “<i>powered by Cryoport<sup style="font-style:normal">SM</sup></i>” appears prominently on the offering software interface and packaging.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif">  </div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> “<strong><i>Integrated Solution</i></strong>” is our most comprehensive and complex solution. It is a fully outsourced solution and usually involves our management of the entire cryogenic logistics process for our client, including the location of our employees at the client’s site to manage the client’s cryogenic logistics function in total.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> “<strong><i>Regenerative Medicine Point-of-Care Repository Solution</i></strong>” is designed for allogeneic therapies. In this model we supply our Cryoport Express<sup style="font-style:normal">®</sup> Shipper package to ship and store cryogenically preserved life science products for up to 6 days (or longer periods with supplementary shippers) at a point-of-care site, with the Cryoport Express<sup style="font-style:normal">®</sup> Shipper serving as a temporary freezer/repository enabling the efficient and effective distribution of temperature sensitive allogeneic cell-based therapies without the expense, inconvenience, and potential costly failure of an on-sight, cryopreservation device. Our customer service professionals monitor each shipment and the return of the shipper for cleaning, quality assurance testing and reuse.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> “<strong><i>Personalized Medicine and Cell-based Immunotherapy Solution</i></strong>” is designed for autologous therapies.   In this model our Cryoport Express<sup style="font-style:normal">®</sup> Shipper package serves as an enabling technology for the safe transportation of manufactured autologous cellular-based immunotherapy market by providing a comprehensive logistics solution for the verified chain of custody and condition transport from, (a) the collection of the patient’s cells in a hospital setting, to (b) a central processing facility where they are manufactured into a personalized medicine, to (c) the safe, cryogenically preserved return of these irreplaceable cells to a point-of-care treatment facility.  If required, the Cryoport Express<sup style="font-style:normal">®</sup> Shipper can then serve as a temporary freezer/repository to allow the efficient distribution of this personalized medicine to the patient when and where the medical provider needs it most without the expense, inconvenience, and potential costly failure of an on-sight, cryopreservation device. Our customer services professionals monitor each shipment and the return of the shipper for cleaning, quality assurance testing and reuse.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> In December 2012, we signed an agreement with Pfizer Inc. relating to Zoetis Inc. (formerly the animal health business unit of Pfizer Inc.) pursuant to which we were engaged to manage frozen shipments of a key poultry vaccine. Under this arrangement, Cryoport provides on-site logistics personnel and its logistics management operating platform, the Cryoportal<sup style="font-style:normal">TM</sup> to manage shipments from the Zoetis manufacturing site in the United States to domestic customers as well as various international distribution centers. As part of our logistics management services, Cryoport is constantly analyzing logistics data and processes to further introduce economies and reliability throughout the network, ensuring products arrive at their destinations in specified conditions, on-time and with the optimum utilization of resources. The Company manages Zoetis’ total fleet of dewar flask shippers used for this purpose, including liquid nitrogen shippers. In July 2013 the agreement was amended to expand Cryoport’s scope to manage all logistics of Zoetis’ key frozen poultry vaccine to all Zoetis’ international distribution centers as well as all domestic shipments. In October 2013, the agreement was further amended to further expand Cryoport’s role to include the logistics management for a second poultry vaccine.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In January 2013, we entered into a master agreement with Federal Express Corporation (“FedEx”) (“FedEx Agreement”) renewing these services and providing FedEx with a non-exclusive license and right to use a customized version of our Cryoportal<sup style="font-style:normal">TM</sup> for the management of shipments made by FedEx customers. The FedEx Agreement became effective on January 1, 2013 and, unless sooner terminated as provided in the FedEx Agreement, expires on December 31, 2015. FedEx has the right to terminate this agreement at any time for convenience upon 180 days’ notice.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Under our FedEx Agreement, we provide frozen shipping logistics services through the combination of our purpose-built proprietary technologies and turnkey management processes. FedEx markets and sells Cryoport’s services for frozen temperature-controlled cold chain transportation as its FedEx<sup style="font-style:normal">®</sup> Deep Frozen Shipping Solution on a non-exclusive basis and at its sole expense. During fiscal year 2013, the Company worked closely with FedEx to further align its sales efforts and accelerate penetration within FedEx’s life sciences customer base through improved processes, sales incentives, joint customer calls and more frequent communication at the sales and executive level. In addition, FedEx has developed a FedEx branded version of the Cryoportal<sup style="font-style:normal">TM</sup> software platform, which is “<i>powered by Cryoport<sup style="font-style:normal">SM</sup></i>” for use by FedEx and its customers giving them access to the full capabilities of our cloud-based logistics management software platform.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">In February 2014, we entered into a services agreement with Liventa Bioscience, Inc. (“Liventa”), a privately-held, commercial stage biotechnology company focused on cell-based, advanced biologics in the orthopedic industry. Under this agreement, Liventa will use Cryoport’s Regenerative Medicine<strong> </strong> Point-of-Care Repository Solution for the logistics of its cell-based therapies requiring cryogenic temperatures and also provide Cryoport Express<sup style="font-style:normal">®</sup> Solutions to other biologics suppliers within the orthopedic arena. The agreement combines Cryoport’s proprietary, purpose-built cold chain logistics solutions for cell-based and advanced biologic tissue forms with Liventa’s distribution capability to orthopedic care providers.</font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The implementation of Cryoport’s Regenerative Medicine<strong> </strong> Point-of-Care Repository Solution will eliminate the risks of degradation and also eliminate the need for expensive onsite cryogenic freezers for storage of cell-based orthopedic therapies. This will enable Liventa to confidently serve orthopedic practices, surgical centers, pain clinics, hospitals and, eventually, pharmacies and specialty care providers.</font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The agreement has an initial three-year term and may be renewed for consecutive three-year terms, unless earlier terminated by either party. Liventa also agreed to certain performance criteria and the issuance</font> of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 150,000</font> shares of its common stock to Cryoport in exchange for the exclusive right to offer, market and promote Cryoport Express<sup style="font-style:normal">®</sup> Solutions for cellular-based therapies requiring cryogenic temperatures for use in orthopedic in the United States.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In June 2014, we entered into a master agreement with LifeConEx, a part of DHL Global Forwarding (“DHL”). This relationship with DHL is a further implementation of the Company’s expansion of distribution partnerships under the <i>“powered by Cryoport<sup style="font-style:normal">SM</sup></i>” model described above, allowing us to expand our sales and marketing reach through our partners and build awareness of the benefits of our validated cryogenic solution offerings. DHL can now enhance and supplement its cold chain logistics offerings to its life sciences and healthcare customers with Cryoport’s validated cryogenic solutions. DHL added 15 additional certified Life Sciences stations in the second quarter of 2014 bringing the Thermonet network to 60 stations in operation. Over the course of rolling out our new relationship, this expanded network will offer Cryoport’s cryogenic solutions under the DHL brands as “<i>powered by Cryoport<sup style="font-style:normal">SM”</sup></i>.  In addition, DHL’s customers will be able to have direct access to our cloud-based order entry and tracking portal to order Cryoport Express<sup style="font-style:normal">®</sup> Solutions and receive preferred DHL shipping rates and discounts. Our proprietary logistics management operating platform, the Cryoportal<sup style="font-style:normal">TM</sup>, is integrated to DHL’s tracking and billing systems to provide DHL life sciences and healthcare customers with a seamless way of accessing critical information regarding shipments of biological material worldwide.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In October 2014, we added United Parcel Services, Inc. (“UPS”) as our third major distributor by entering into an agreement with UPS Oasis Supply Corporation, a part of UPS, whereby UPS will offer our validated and comprehensive cryogenic solutions to its life sciences and healthcare customers on a global basis. This relationship with UPS is a further implementation of the Company’s expansion of distributors under the <i> “powered by Cryoport<sup style="font-style:normal">SM</sup></i>” model described above, allowing us to further expand our sales and marketing reach through our partners and build awareness of the benefits of our validated cryogenic solution offerings through UPS.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Over the course of rolling out our new relationship with UPS, UPS customers will have direct access to our cloud-based order entry and tracking portal to order Cryoport Express<sup style="font-style:normal">®</sup> Solutions and gain access to UPS’s broad array of domestic and international shipping and logistics solutions at competitive prices. Our proprietary logistics management operating platform, the Cryoportal<sup style="font-style:normal">TM</sup>, is integrated to UPS’s tracking and billing systems to provide UPS life sciences and healthcare customers with a seamless way of accessing critical information regarding shipments of biological material worldwide.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">This relationship with UPS represents the third and final agreement with the “big three” global integrators. Cryoport now serves and supports the three largest integrators in the world with its advanced cryogenic logistics solutions for life sciences. We operate with each independently and confidentially support their respective strategies. These agreements represent a significant validation of our solutions and the way we conduct our business.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In summary, we serve the life sciences industry with cryogenic logistics solutions that are advanced, comprehensive, reliable, validated, and economical. Our clients include those companies and institutions that have logistics requirements for stem cells, cell lines, tissue, vaccines, in-vitro fertilization, cord blood, and other temperature sensitive commodities of life sciences.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Companies or institutions such as therapy developers for personalized medicine, research, bio-pharmaceuticals, contract research organizations, diagnostic laboratories, in-vitro fertilization, cord blood, vaccine manufacturers, animal husbandry, and other producers of commodities requiring reliable logistics solutions for logistics are amongst our clients. These companies usually operate within heavily regulated environments and as such, changing vendors and distribution practices typically require a number of steps, which may include the audit of our facilities, review of our procedures, qualifying us as a vendor, and performing test shipments. This process can take three to nine months or longer to complete prior to a potential customer adopting one or more of our Cryoport Express<sup style="font-style:normal">®</sup> Solutions.</font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Going Concern</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The unaudited condensed consolidated financial statements have been prepared using the accrual method of accounting in accordance with U.S. GAAP and have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. We have sustained operating losses since our inception and have used substantial amounts of working capital in our operations. At September 30, 2014, we had an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">92.0</font> million. During the six months ended September 30, 2014, we used cash in operations of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.8</font> million and had a net loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.7</font> million.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-SIZE: 10pt">We expect to continue to incur substantial additional operating losses from costs related to the commercialization of our Cryoport Express<sup style="font-style:normal">®</sup></font> <font style="FONT-SIZE: 10pt">Solutions and do not expect that revenues from operations will be sufficient to satisfy our funding requirements in the near term. We believe that our cash resources at September 30, 2014, additional funds raised subsequent to September 30, 2014 through the current convertible preferred stock offering (see Note 9), together with the revenues generated from our services will be sufficient to sustain our planned operations into the third quarter of fiscal year 2015; however, we must obtain additional capital to fund operations thereafter and for the achievement of sustained profitable operations. These factors raise substantial doubt about our ability to continue as a going concern. We are currently working on funding alternatives in order to secure sufficient operating capital to allow us to continue to operate as a going concern.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-SIZE: 10pt">Future capital requirements will depend upon many factors, including the success of our commercialization efforts and the level of customer adoption of our Cryoport Express<sup style="font-style:normal">®</sup></font> <font style="FONT-SIZE: 10pt">Solutions as well as our ability to establish additional collaborative arrangements. We cannot make any assurances that the sales ramp will lead to achievement of sustained profitable operations or that any additional financing will be completed on a timely basis and on acceptable terms or at all. Management’s inability to successfully achieve significant revenue increases or implement cost reduction strategies or to complete any other financing will adversely impact our ability to continue as a going concern. To address this issue, the Company is seeking additional capitalization to properly fund our efforts to become a self-sustaining financially viable entity.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	Cryoport, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001124524
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	CYRX
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	60057846	shares
	cyrx	Maturity Period Of Highly Liquid Investments MaturityPeriodOfHighlyLiquidInvestments	P90D
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	13161017	USD
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	0	USD
CY2013Q3	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	13161017	USD
CY2014Q3	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	0	USD
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	1766997	USD
CY2014Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.05	pure
CY2014Q1	cyrx	Accrued Interest Related Party AccruedInterestRelatedParty	802600	USD
CY2014Q3	cyrx	Accrued Interest Related Party AccruedInterestRelatedParty	818700	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9000	USD
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9000	USD
CY2014Q3	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	12.00

Files In Submission

Name	View Source	Status
0001144204-14-067082-index-headers.html	Edgar Link	pending
0001144204-14-067082-index.html	Edgar Link	pending
0001144204-14-067082.txt	Edgar Link	pending
0001144204-14-067082-xbrl.zip	Edgar Link	pending
cyrx-20140930.xml	Edgar Link	completed
cyrx-20140930.xsd	Edgar Link	pending
cyrx-20140930_cal.xml	Edgar Link	unprocessable
cyrx-20140930_def.xml	Edgar Link	unprocessable
cyrx-20140930_lab.xml	Edgar Link	unprocessable
cyrx-20140930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v391638_10q.htm	Edgar Link	pending
v391638_ex31-1.htm	Edgar Link	pending
v391638_ex31-2.htm	Edgar Link	pending
v391638_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CYRX
Cryoport, Inc. Stock $cyrx

2014 Q4 Form 10-Q Financial Statement

#000114420414067082 Filed on November 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYRX Cryoport, Inc. Stock $cyrx

2014 Q4 Form 10-Q Financial Statement

#000114420414067082 Filed on November 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYRX
Cryoport, Inc. Stock $cyrx